Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
China · Delayed Price · Currency is CNY 36.79
-0.42 (-1.13%)
Aug 11, 2026, 3:00 PM CST
SHA:600329 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 24,924 | 30,778 | 20,699 | 22,121 | 18,246 | 19,473 | |
Market Cap Growth | -6.77% | 48.69% | -6.43% | 21.24% | -6.30% | 73.88% |
Enterprise Value | 23,214 | 29,079 | 20,519 | 20,903 | 16,178 | 17,504 |
Last Close Price | 37.21 | 40.72 | 26.45 | 27.79 | 23.52 | 24.81 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.16 | 14.44 | 9.29 | 22.42 | 21.17 | 25.32 |
Forward PE | - | 24.66 | 18.40 | 20.04 | 22.73 | 22.87 |
PS Ratio | 5.01 | 6.26 | 2.83 | 2.69 | 2.21 | 2.82 |
PB Ratio | 3.31 | 4.34 | 2.64 | 3.33 | 2.79 | 2.99 |
P/TBV Ratio | 3.45 | 4.52 | 2.75 | 3.56 | 2.96 | 3.16 |
P/FCF Ratio | 59.81 | 89.88 | 25.65 | 40.40 | 32.05 | 28.00 |
P/OCF Ratio | 47.23 | 66.75 | 22.39 | 32.13 | 26.94 | 22.85 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.66 | 5.91 | 2.81 | 2.54 | 1.96 | 2.53 |
EV/EBITDA Ratio | 20.51 | 28.33 | 22.91 | 22.06 | 20.58 | 24.96 |
EV/EBIT Ratio | 22.68 | 31.68 | 26.51 | 25.46 | 24.10 | 29.82 |
EV/FCF Ratio | 55.71 | 84.92 | 25.43 | 38.17 | 28.42 | 25.17 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.05 | 0.04 | 0.01 |
Debt / EBITDA Ratio | 0.05 | 0.07 | 0.04 | 0.36 | 0.34 | 0.06 |
Debt / FCF Ratio | 0.14 | 0.22 | 0.05 | 0.62 | 0.47 | 0.06 |
Net Debt / Equity Ratio | -0.23 | -0.60 | -0.50 | -0.28 | -0.40 | -0.36 |
Net Debt / EBITDA Ratio | -1.51 | -4.15 | -4.36 | -1.95 | -3.38 | -3.35 |
Net Debt / FCF Ratio | -4.10 | -12.43 | -4.84 | -3.37 | -4.66 | -3.38 |
Asset Turnover | 0.46 | 0.44 | 0.70 | 0.81 | 0.86 | 0.80 |
Inventory Turnover | 1.11 | 1.09 | 2.67 | 3.09 | 3.38 | 2.76 |
Quick Ratio | 1.26 | 1.31 | 1.87 | 1.51 | 1.71 | 1.81 |
Current Ratio | 2.16 | 1.59 | 2.35 | 2.03 | 2.17 | 2.64 |
Return on Equity (ROE) | 27.46% | 28.24% | 30.56% | 14.68% | 13.37% | 12.63% |
Return on Assets (ROA) | 5.92% | 5.11% | 4.61% | 5.03% | 4.37% | 4.23% |
Return on Invested Capital (ROIC) | 20.09% | 22.95% | 15.21% | 16.70% | 14.84% | 12.96% |
Return on Capital Employed (ROCE) | 13.50% | 12.80% | 9.70% | 11.70% | 9.80% | 8.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.75% | 6.92% | 10.77% | 4.46% | 4.72% | 3.95% |
FCF Yield | 1.67% | 1.11% | 3.90% | 2.48% | 3.12% | 3.57% |
Dividend Yield | 12.58% | 11.76% | 4.84% | 4.61% | 4.76% | 2.02% |
Payout Ratio | 131.09% | 46.05% | 45.33% | 88.91% | 44.96% | 30.17% |
Buyback Yield / Dilution | -0.30% | 0.27% | -0.07% | 0.71% | -0.94% | 0.04% |
Total Shareholder Return | 12.28% | 12.03% | 4.77% | 5.32% | 3.82% | 2.05% |